uniQure (NASDAQ:QURE – Get Free Report) and Longeveron (NASDAQ:LGVN – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Risk and Volatility
uniQure has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Longeveron has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500.
Insider and Institutional Ownership
78.8% of uniQure shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| uniQure | 1 | 2 | 12 | 1 | 2.81 |
| Longeveron | 1 | 1 | 1 | 0 | 2.00 |
uniQure currently has a consensus target price of $56.64, suggesting a potential upside of 141.42%. Longeveron has a consensus target price of $80.00, suggesting a potential upside of 3,000.78%. Given Longeveron’s higher possible upside, analysts plainly believe Longeveron is more favorable than uniQure.
Valuation & Earnings
This table compares uniQure and Longeveron”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| uniQure | $18.67 million | 87.15 | -$198.97 million | ($4.01) | -5.85 |
| Longeveron | $1.20 million | 6.86 | -$22.70 million | ($9.90) | -0.26 |
Longeveron has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares uniQure and Longeveron’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| uniQure | -1,350.73% | -111.96% | -29.01% |
| Longeveron | -1,977.59% | -223.19% | -150.20% |
Summary
uniQure beats Longeveron on 11 of the 15 factors compared between the two stocks.
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
